#United States #biotechnology #Boulder #Series A #Think Bioscience

Think Bioscience Secures $55 Million in Series A Funding

Boulder, Colorado — In a significant advancement for biopharmaceutical innovation, Think Bioscience, a biotechnology firm dedicated to developing drugs for hard-to-target diseases, has successfully raised $55 million through an oversubscribed Series A financing round. This investment marks a pivotal moment for the firm, which aims to unlock potential therapies for conditions that previously lacked effective treatment options.

Led by esteemed investors like Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors, the funding round also saw participation from noteworthy sources including T.A. Springer, CE-Ventures, MBX Capital, and YK Bioventures. The company also attracted returning support from investors such as AV8 Ventures, CU Innovations, and Buff Gold Ventures.

Think Bioscience is gaining recognition for its innovative approach in the biopharmaceutical arena by advancing small molecule drugs aimed at challenging drug targets. The company's flagship program specifically addresses the needs of patients with Noonan syndrome—a genetic disorder that impacts approximately 1 in 2,500 births, causing severe cardiac issues, growth deficiencies, cognitive challenges, and other significant health concerns. Currently, there are no approved therapies that tackle the underlying biology of Noonan syndrome.

Dr. Jerome Fox, co-founder and CEO of Think Bioscience, expressed gratitude to their investors, highlighting the transformative potential of their lead program: "Our primary focus is to enhance the lives of patients suffering from Noonan syndrome. This funding bolsters our commitment to developing life-changing therapies."

Despite advancements in computational chemistry, creating effective drugs remains extraordinarily difficult. Many proteins in the human genome are labeled as undruggable due to the absence of suitable binding sites. Think Bioscience leverages a synthetic biology infrastructure, employing high-throughput functional assessments to identify novel binding pockets that are often overlooked. This approach allows the development of small molecules with therapeutic activities that were once deemed unachievable.

The versatility of Think Bioscience's platform extends to various types of targets, such as transcription factors, protein phosphatases, kinases, and proteases, while maintaining a robust internal pipeline that showcases their growing expertise.

Nick Olsen, a partner at Innovation Endeavors, praised the efforts of the Think Bioscience team, stating, "This team is succeeding where others have failed with their innovative approaches. The lead program is promising, but it's merely one example of a myriad of initiatives that the company is pursuing. We are eager to support them and accelerate their impactful work."

About Think Bioscience

Founded in Boulder, Colorado, Think Bioscience is a privately-held entity specializing in small molecule drug discovery. The company's mission is to tackle challenging therapeutic targets often considered undruggable. Their multidisciplinary team merges knowledge from synthetic biology, protein biophysics, applied enzymology, computational chemistry, and medicinal chemistry to pioneer first-in-class programs addressing diseases with unfulfilled medical demands. To learn more about their groundbreaking work, visit www.thinkbioscience.com.